EU Panel Backs Adjuvant Nivolumab for Melanoma

June 29, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, according to Bristol-Myers Squibb, the developer of the PD-1 inhibitor. The recommendation is based on findings from the phase III CheckMate-238 trial, in which the recurrence-free … (leggi tutto)